Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.